StemCells, Inc. Adds Byers Eye Institute at Stanford as Second Site for Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration

[at noodls] – NEWARK, Calif., April 18, 2013 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM) today announced the addition of the Byers Eye Institute at Stanford, located in Palo Alto, Calif., as a second site for … more

View todays social media effects on STEM

View the latest stocks trending across Twitter. Click to view dashboard

See who StemCells is hiring next, click here to view